FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786284823> ?p ?o ?g. }

• W2786284823 abstract "Background: The human epidermal growth factor type 2 (HER2) receptor is a membrane glycoprotein tyrosine kinase. In woman, HER2 expression is diagnosed in 30% of breast carcinomas and it is associated with a worse prognosis, higher rate of recurrence and mortality. In the bitch, the HER2 overexpression in canine mammary tumors is still controversial and the prognostic value remains uncertain. Thus, we aimed to verify the HER2 expression in canine mammary carcinomas and relate it to the type and histological grade, lymph node metastasis and clinical staging.Materials, Methods & Results: Ninety bitches diagnosed with mammary carcinoma were included in this study. The inclusion criteria were bitches with complete clinical examination, thoracic radiographic examination and submitted unilateral or bilateral mastectomy. Ninety-nine samples of mammary carcinoma were used and the fragments of tumor and regional lymph nodes were fixed in 10% neutral formalin for histopathological and immunohistochemistry analysis. The lesions were evaluated by two pathologists and classified according to the type and histological grade. HER2 expression was performed by semi-quantitative analysis of the slides according to the HerceptTestTM (Dako) recommended score. Simple carcinomas were the most frequent (51.51%) followed by complex carcinomas (46.47%) and in situ carcinoma (2.02%). The histological grade of 97 carcinoma samples was attributed, except in situ carcinoma, 37 (38.14%) of the neoplasms were grade I, 50 (51.55%) grade II and only 10 (10.31%) tumors were classified as grade III. Forty bitches were submitted to clinical staging (TNM) and 42.50% of the bitches received staging in grade I and, 25% of the bitches staged in grade IV and V, with metastases. The HER2 expression, 13/99 samples (13.13%) received score +2, 19/99 (19.19%) score +1 and absence of marking (score 0) was identified in 67 samples (67.80 %). Immunostaining in hyperplastic or normal epithelial cells was evidenced, often in association with weak or moderate cytoplasmic labeling. Of the samples expressing +2 score for HER2 (n = 13), eight samples (17.39%) were complex carcinoma and five (9.80%) simple carcinomas. There was no relationship between HER2 immunostaining with age, tumor size, TNM, histological type, histological gradation, lymph node metastasis and distance. Animals with lymph node metastasis, as well as those diagnosed with distant metastasis, did not present HER2 expression in the tumors.Discussion: The simple carcinoma seems to be the most frequent type histological diagnosed in canine mammary carcinomas, followed by carcinoma in mixed tumor and complex carcinoma. Tubulopapillary carcinomas are more invasive in the female dogs as well as in the woman. Carcinomas grade I and II are more frequent and present a better prognosis for the dog. However, bitches with grade III carcinoma survived for a shorter time when compared to dogs with grade I or II tumors. A factor that may have contributed to the lower number of bitches at worst prognostic stage (EC IV and V) is the current owners’ awareness that they have sought veterinary help earlier, as soon as they detect small nodules in mammary gland. Overexpression of HER2 in women breast cancer is diagnosed in 20-30% of cases, whereas in bitches, this expression is variable. Also the different percentages of canine HER2 immunostaining are due to the lack of standardization for the analysis of the immunostaining, the immunohistochemical techniques employed and the non-specificity of the HER2 antibody. In canine mammary carcinomas the HER2 expression in low and this immunostaining is not related to other established prognostic factors. This study reinforces the hypothesis put forward by other authors that in the bitch the expression of HER2 may not be related to malignancy and tumor progression." @default.
• W2786284823 created "2018-02-23" @default.
• W2786284823 creator A5001112098 @default.
• W2786284823 creator A5016537066 @default.
• W2786284823 creator A5043056577 @default.
• W2786284823 creator A5051941142 @default.
• W2786284823 creator A5066076952 @default.
• W2786284823 creator A5088976708 @default.
• W2786284823 date "2017-06-09" @default.
• W2786284823 modified "2023-09-26" @default.
• W2786284823 title "Prognostic Factors in Canine Mammary Carcinomas and HER2 Expression Relationship" @default.
• W2786284823 doi "https://doi.org/10.22456/1679-9216.79791" @default.
• W2786284823 hasPublicationYear "2017" @default.
• W2786284823 type Work @default.
• W2786284823 sameAs 2786284823 @default.
• W2786284823 citedByCount "1" @default.
• W2786284823 countsByYear W27862848232019 @default.
• W2786284823 crossrefType "journal-article" @default.
• W2786284823 hasAuthorship W2786284823A5001112098 @default.
• W2786284823 hasAuthorship W2786284823A5016537066 @default.
• W2786284823 hasAuthorship W2786284823A5043056577 @default.
• W2786284823 hasAuthorship W2786284823A5051941142 @default.
• W2786284823 hasAuthorship W2786284823A5066076952 @default.
• W2786284823 hasAuthorship W2786284823A5088976708 @default.
• W2786284823 hasBestOaLocation W27862848231 @default.
• W2786284823 hasConcept C121608353 @default.
• W2786284823 hasConcept C126322002 @default.
• W2786284823 hasConcept C142724271 @default.
• W2786284823 hasConcept C204232928 @default.
• W2786284823 hasConcept C2777546739 @default.
• W2786284823 hasConcept C2778001805 @default.
• W2786284823 hasConcept C2779013556 @default.
• W2786284823 hasConcept C2780849966 @default.
• W2786284823 hasConcept C3018521938 @default.
• W2786284823 hasConcept C530470458 @default.
• W2786284823 hasConcept C544855455 @default.
• W2786284823 hasConcept C71924100 @default.
• W2786284823 hasConceptScore W2786284823C121608353 @default.
• W2786284823 hasConceptScore W2786284823C126322002 @default.
• W2786284823 hasConceptScore W2786284823C142724271 @default.
• W2786284823 hasConceptScore W2786284823C204232928 @default.
• W2786284823 hasConceptScore W2786284823C2777546739 @default.
• W2786284823 hasConceptScore W2786284823C2778001805 @default.
• W2786284823 hasConceptScore W2786284823C2779013556 @default.
• W2786284823 hasConceptScore W2786284823C2780849966 @default.
• W2786284823 hasConceptScore W2786284823C3018521938 @default.
• W2786284823 hasConceptScore W2786284823C530470458 @default.
• W2786284823 hasConceptScore W2786284823C544855455 @default.
• W2786284823 hasConceptScore W2786284823C71924100 @default.
• W2786284823 hasLocation W27862848231 @default.
• W2786284823 hasOpenAccess W2786284823 @default.
• W2786284823 hasPrimaryLocation W27862848231 @default.
• W2786284823 hasRelatedWork W2000477149 @default.
• W2786284823 hasRelatedWork W2010062423 @default.
• W2786284823 hasRelatedWork W2028678591 @default.
• W2786284823 hasRelatedWork W2061771066 @default.
• W2786284823 hasRelatedWork W2110805273 @default.
• W2786284823 hasRelatedWork W2144104692 @default.
• W2786284823 hasRelatedWork W2187853319 @default.
• W2786284823 hasRelatedWork W2241547178 @default.
• W2786284823 hasRelatedWork W2276267373 @default.
• W2786284823 hasRelatedWork W2367642123 @default.
• W2786284823 hasRelatedWork W2381756892 @default.
• W2786284823 hasRelatedWork W2461093456 @default.
• W2786284823 hasRelatedWork W2464341334 @default.
• W2786284823 hasRelatedWork W2589016339 @default.
• W2786284823 hasRelatedWork W2887638391 @default.
• W2786284823 hasRelatedWork W2888201700 @default.
• W2786284823 hasRelatedWork W2902425373 @default.
• W2786284823 hasRelatedWork W2948241995 @default.
• W2786284823 hasRelatedWork W3020123415 @default.
• W2786284823 hasRelatedWork W3210128856 @default.
• W2786284823 isParatext "false" @default.
• W2786284823 isRetracted "false" @default.
• W2786284823 magId "2786284823" @default.
• W2786284823 workType "article" @default.